Compare CING & SKYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CING | SKYA |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3M | 52.9M |
| IPO Year | N/A | 2022 |
| Metric | CING | SKYA |
|---|---|---|
| Price | $4.84 | $1.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 331.9K | 306.3K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.91 |
| 52 Week High | $11.89 | $1.26 |
| Indicator | CING | SKYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 56.60 |
| Support Level | $4.94 | $0.91 |
| Resistance Level | $5.30 | $1.26 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 21.15 | 68.73 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.